Erratum to: Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia (Movement Disorders, (2016), 31, 8, (1203-1208), 10.1002/mds.26668);Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia

Movement Disorders

Volumn 31, Issue 8, 2016, Pages 1203-1208

  Abdelnour, Carla ^a   van Steenoven, Inger ^b   Londos, Elisabet ^c   Blanc, Frédéric ^d   Auestad, Bjørn ^e,f   Kramberger, Milica G ^g   Zetterberg, Henrik ^h,i   Mollenhauer, Brit ^j   Boada, Mercè ^a   Aarsland, Dag ^e,k  

^a Institut Catala de Neurociencies Aplicades   (Spain)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF STAVANGER   (Norway)

^g UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^k KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

cognitive decline; CSF biomarkers; Lewy body dementia

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PHOSPHOPROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; EDUCATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; CLINICAL TRIAL; DEMENTIA ASSESSMENT; DISEASE EXACERBATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEWY BODY DISEASE; MALE; MENTAL STATUS AND DEMENTIA TESTS; PEPTIDE FRAGMENTS; PROGNOSIS; TAU PROTEINS;

EID: 84978394442     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27672     Document Type: Erratum

References (37)

1. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015;386:1683-1697.
2. Mollenhauer B, Parnetti L, Rektorova I, et al. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. J Neurochem 2015 Oct 10. doi: 10.1111/jnc.13390. [Epub ahead of print]
3. Howlett DR, Whitfield D, Johnson M, et al. Regional Multiple Pathology Scores are associated with cognitive decline in Lewy body dementias. Brain Pathol 2015;25:401-408.
4. Kraybill ML, Larson EB, Tsuang D, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005;64:2069-2073.
5. Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments. Curr Opin Psychiatry 2015;28:402-409.
6. Schoonenboom N, Reesink F, Verwey N, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012;78:47-54.
7. Buongiorno M, Compta Y, Martí MJ. Amyloid-β and τ biomarkers in Parkinson's disease-dementia. J Neurol Sci 2011;310:25-30.
8. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.
9. Brunnström H, Hansson O, Zetterberg H, Londos E, Englund E. Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. Int J Geriatr Psychiatry 2013;28:738-744.
10. McKeith I, Dickson D, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
11. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimers Dement 2014;10:713-723.
13. R Foundation for Statistical Computing. R: A language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2014.
14. Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. J Alzheimers Dis 2014;38:63-73.
15. Gomperts SN. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr Neurol Neurosci Rep 2014;14:472.
16. Slaets S, Le Bastard N, Theuns J, et al. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis 201335:137-146.
17. Wang ZY, Han ZM, Liu QF, Tang W, Ye K, Yao YY. Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders. Int Psychogeriatr 2015;27:1429-1438.
18. Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015;84:57-63.
19. Liu C, Cholerton B, Shi M, et al. CSF tau and tau/Aβ 42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat Disord 2015;21:271-276.
20. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22:200-208.
21. Parnetti L, Farotti L, Eusebi P, et al. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's disease. Front Aging Neurosci 2014;6:53.
22. Terrelonge M, Jr., Marder KS, Weintraub D, Alcalay RN. CSF β-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci 2016;58:88-92.
23. Alves G, Brønnick K, Aarsland D, et al. CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81:1080-1086.
24. Boström F, Hansson O, Blennow K, et al. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2009;28:314-319.
25. Vanderstichele H, De Vreese K, Blennow K, et al. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU (181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006;44:1472-1480.
26. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Aβ, tau, and α-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010;30:7281-7289.
27. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015;86:135-143.
28. Wang CS, Pai MC, Chen PL, Hou NT, Chien PF, Huang YC. Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer's disease, and normal participants in Taiwan. Int Psychogeriatr 2013;25:1839-1848.
29. Biundo R, Weis L, Bostantjopoulou S, et al. MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm (Vienna) 2016;123:431-438.
30. Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease. Parkinsonism Relat Disord 2014;20:1145-1148.
31. Hansson O, Hall S, Öhrfelt A, et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther 2014;6:1-6.
32. 1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci 2014;343:120-124.
33. Wennström M, Hall S, Nägga K, Londos E, Minthon L, Hansson O. Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. Alzheimers Res Ther 2015;7:1-8.
34. Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H. Novel Aβ isoforms in Alzheimer's disease—their role in diagnosis and treatment. Curr Pharm Des 2011;17:2594-2602.
35. Ballard C, O'Brien J, Morris CM, Barber R, Swann A, Neil D, McKeith I. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2011;16:499-503.
36. Lebedev AV, Westman E, Beyer M, et al. Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. J Neurol 2013;260:1104-1115.
37. McKeith I, Ballard C, Perry R, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058.